Please ensure Javascript is enabled for purposes of website accessibility

Why Affymetrix, Inc. Shares Dropped

By Sean Williams - Feb 6, 2014 at 1:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Affymetrix shares slump after reporting its fourth-quarter earnings results. Is this dip a buying opportunity or a warning sign for investors?

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Affymetrix (AFFX.DL), a life science tools and molecular diagnostic manufacturer, dipped as much as 17% after the company reported its fourth quarter earnings results after the bell last night.

So what: For the quarter, Affymetrix delivered a 10% increase in year over year revenue to $92.6 million as adjusted profits improved to $0.02 per share on a 5% increase in gross margin to 59%, reversing a $0.02 per share year-ago net loss. By comparison, though, Wall Street had been expecting only $91 million in revenue, but was looking for a more robust $0.07 in fourth-quarter EPS.

Now what: This has pretty much been the story with Affymetrix for as long as my mind can recall. Namely, plenty of promise on paper, but an inability to deliver bottom-line growth on any consistent basis. Thus far, it appears Affymetrix's purchase of eBioscience is aiding revenue growth nicely, but not providing the profitable impact that many shareholders had hoped for. Once again, on paper Affymetrix makes a world of sense given that baby boomers are aging and the push toward using genetic tests to personalize medical treatments is only likely to gain steam in the coming years. However, a tough spending environment perpetuated by funding cuts from the U.S. government and Affymetrix's inability to really trim its costs any further make it a somewhat expensive gamble here even following today's drop.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Affymetrix Inc. Stock Quote
Affymetrix Inc.
AFFX.DL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.